Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
178 stopped studies mapped to Triple-Negative Breast Carcinoma and descendants · 97% state a reason
Over the 178 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting…(neoBREASTIM) | Phase 1 / Phase 2 | terminated | Oct 4, 2023 | Institut Curie | insufficient recruitment | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients…(PERSEVERE) | Phase 2 | terminated | Apr 19, 2021 | Bryan Schneider, MD | Funder Decision | Other (stated, no rule matched) |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | Numab Therapeutics AG | A business decision was made to discontinue further enrollment. There were no safety concerns that… | Safety / toxicity |
| NCT03742349 | Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple… | Phase 1 | terminated | Nov 15, 2018 | Novartis Pharmaceuticals | This was a sponsor decision and was not a consequence of any safety concern | Safety / toxicity |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT05336721 | A Phase II Study of Chiauranib in Combine With Capecitabine in TNBC | Phase 2 | terminated | Apr 20, 2022 | Chipscreen Biosciences, Ltd. | During the enrollment period of this project, due to the increasing proportion of patients… | Enrollment / accrual |
| NCT03175666 | QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy… | Phase 1 / Phase 2 | withdrawn | Jun 5, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03554109 | QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine(TNBC) | Phase 2 | withdrawn | Jun 12, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05113966 | Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast… | Phase 2 | terminated | Nov 9, 2021 | G1 Therapeutics, Inc. | The Sponsor decided to close enrollment to the study on Feb 14, 2023, in order to reallocate… | Enrollment / accrual |
| NCT05539365 | Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or… | Phase 2 | withdrawn | Sep 14, 2022 | Roswell Park Cancer Institute | Study never activated. | Other (stated, no rule matched) |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT03473691 | Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant…(Breast50) | Early Phase 1 | withdrawn | Mar 22, 2018 | University of Virginia | Pharmaceutical company decided to withdraw funding and not provide drug. | Funding |
| NCT05177796 | Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the… | Phase 2 | withdrawn | Jan 5, 2022 | M.D. Anderson Cancer Center | 0 participants recruited | Enrollment / accrual |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who… | Phase 2 | terminated | Mar 13, 2019 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | Phase 2 | terminated | Oct 11, 2019 | Xiang Zhang | Terminated by sponsor due to lack of interest | Other (stated, no rule matched) |
| NCT04835597 | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant… | — | terminated | Apr 8, 2021 | M.D. Anderson Cancer Center | IRB Study Closure | Other (stated, no rule matched) |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant…(IMpassion030) | Phase 3 | terminated | Apr 17, 2018 | Hoffmann-La Roche | The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS… | Efficacy / futility |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04927884 | A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast… | Phase 1 / Phase 2 | terminated | Jun 16, 2021 | ImmunityBio, Inc. | low enrollment | Enrollment / accrual |
| NCT03199040 | Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple… | Phase 1 | terminated | Jun 26, 2017 | Washington University School of Medicine | Drugs/equipment unavailable and insufficient funding | Funding |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | N/A | withdrawn | Sep 28, 2023 | The University of Tennessee, Knoxville | Unable to recruit participants | Enrollment / accrual |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy… | Phase 3 | terminated | Nov 24, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor R \& D Strategy Adjustment\] | Sponsor / business decision |
| NCT03361800 | Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage… | Early Phase 1 | terminated | Dec 5, 2017 | UNC Lineberger Comprehensive Cancer Center | Funding withdrawn. | Funding |
| NCT04691375 | A Study of PY314 in Subjects With Advanced Solid Tumors | Phase 1 | terminated | Dec 31, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast…(TENACITY) | Phase 2 | terminated | Jul 8, 2020 | Ayala Pharmaceuticals, Inc, | Sponsor's decision | Sponsor / business decision |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants… | Phase 1 / Phase 2 | terminated | Jun 20, 2019 | pharmaand GmbH | Due to a change in development priorities, no further clinical development of the lucitanib plus… | Other (stated, no rule matched) |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative…(TARA) | Phase 2 | terminated | Dec 31, 2020 | Mylin A. Torres, MD | This study has been terminated due to Lack of Accrual. | Enrollment / accrual |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus… | Phase 1 | terminated | Mar 4, 2019 | Leap Therapeutics, Inc. | Product development discontinued unrelated to safety. | Safety / toxicity |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | Phase 1 | terminated | Oct 25, 2019 | Mayo Clinic | poor accrual | Enrollment / accrual |
| NCT04441099 | NBE-002 in Patients With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jun 22, 2020 | NBE-Therapeutics AG | End of Program | Other (stated, no rule matched) |
| NCT04185311 | Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating… | Phase 1 | terminated | Dec 4, 2019 | Jonsson Comprehensive Cancer Center | enrollment | Enrollment / accrual |
| NCT04639245 | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous… | Phase 1 / Phase 2 | terminated | Nov 20, 2020 | Fred Hutchinson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 3, 2018 | Genmab | Sponsor decision | Sponsor / business decision |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid… | Phase 1 / Phase 2 | terminated | Jun 11, 2020 | Genmab | Study was terminated due to MTD was reached | Other (stated, no rule matched) |
| NCT05809895 | Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With…(AdvanTIG-211) | Phase 2 | withdrawn | Apr 12, 2023 | Novartis Pharmaceuticals | Business decision, not driven by safety concerns; no new safety signals have been observed in the… | Safety / toxicity |
| NCT05255666 | Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer… | Phase 2 | withdrawn | Feb 24, 2022 | Washington University School of Medicine | No drug | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 14, 2025source: clinicaltrials